The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment

Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment

May 17, 2018 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Just as meteorologists use their technological tools to try to predict future weather patterns, rheumatologists are increasingly investigating how imaging can be used as a biomarker of GCA disease activity. Grayson and colleagues have conducted a study in 56 patients with large-vessel vasculitis and 59 comparator subjects (individuals with hyperlipidemia, diseases that mimic large-vessel vasculitis and healthy controls) in which FDG-PET imaging studies were conducted at six-month intervals.1 This study demonstrated that a qualitative summary score based on global arterial FDG uptake could be used to predict clinical relapse over a median follow-up period of 15 months. Such a finding is very helpful to the rheumatologist seeking to forecast which GCA patients may flare over time.

You Might Also Like
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • New Insights into the Management of Giant Cell Arteritis
  • Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
Explore This Issue
May 2018
Also By This Author
  • DADA2: A New Disease for Rheumatologists to Understand

Interestingly, FDG-PET scans were interpreted as showing active disease in 41 of 71 large-vessel vasculitis patients in clinical remission, perhaps indicating that this modality can show subclinical phenomena not readily apparent to the clinician at the bedside.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Complications

The topic of GCA is not without rain and thunderstorms, and unfortunate adverse outcomes exist that rheumatologists should think about routinely. Among these are infections, venous thrombosis and blindness. The risk of infection is greatest for patients in the first six to 12 months after diagnosis, and risk factors for infection include advanced age, diabetes and dose and duration of corticosteroid therapy.

Venous thromboembolism has been reported in up to 6% of GCA patients in some studies, with a five-month median duration between GCA diagnosis and thromboembolic event, and a median prednisone dose of 17 mg/day at the time of the event. The potential for blindness is perhaps the best known and most feared complication in GCA. Yates and colleagues compared 34 GCA patients who developed blindness at six months with 399 who did not develop blindness at six months and found peripheral vascular disease, diabetes and history of stroke at a statistically significantly higher prevalence in the former than in the latter group.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Blue Skies Ahead

In closing the talk, Dr. Manno discussed the reason rheumatologists should see rays of sunshine through the clouds. She was referring to the Giant-Cell Arteritis Actemra (GiACTA) trial, published this past year in the New England Journal of Medicine.3

In this phase 2, randomized, placebo-controlled study from Stone and colleagues, 251 patients with GCA were randomized to one of four groups: 1) weekly tocilizumab (Actemra) with a 26-week prednisone taper, 2) every other week tocilizumab with a 26-week prednisone taper, 3) weekly placebo with a 26-week prednisone taper, and 4) weekly placebo with a 52-week prednisone taper.

Pages: 1 2 3 | Single Page

Filed Under: Vasculitis Tagged With: Giant Cell Arteritis, tocilizumabIssue: May 2018

You Might Also Like:
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • New Insights into the Management of Giant Cell Arteritis
  • Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
  • Giant Cell Arteritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.